aTyr Pharma to Present at September Investor Conferences
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged
in the discovery and development of innovative medicines based on
novel immunological pathways, today announced that the company will
present at two investor conferences in September.
Sanjay S. Shukla, M.D., M.S., President and
Chief Executive Officer, will present a company update at the H.C.
Wainwright 22nd Annual Global Investment Conference, which is being
held September 14-16, and the Oppenheimer Fall Healthcare Life
Sciences & MedTech Summit, which is being held September 21-23.
Both conferences will take place in a virtual format.
Details of the events are as follows: Conference: H.C.
Wainwright 22nd Annual Global Investment ConferenceDate: Tuesday
September 15, 2020 Presentation Time: 10:30 a.m. Eastern Time
Conference: Oppenheimer Fall Healthcare Life Sciences &
MedTech SummitDate: Tuesday September 22, 2020 Presentation Time:
10:50 a.m. Eastern Time
A replay of the live webcast of each
presentation will be available on the Investor’s section of the
Company’s website at www.atyrpharma.com, and will be available for
90 days following each event.
aTyr is a biotherapeutics company engaged in the
discovery and development of innovative medicines based on novel
immunological pathways. aTyr’s research and development efforts are
concentrated on a newly discovered area of biology, the
extracellular functionality and signaling pathways of tRNA
synthetases. aTyr has built a global intellectual property estate
directed to a potential pipeline of protein compositions derived
from 20 tRNA synthetase genes and their extracellular targets.
aTyr’s primary focus is ATYR1923, a clinical-stage product
candidate which binds to the neuropilin-2 receptor and is designed
to down-regulate immune engagement in inflammatory lung diseases.
For more information, please visit http://www.atyrpharma.com.